PAR 4.65% 22.5¢ paradigm biopharmaceuticals limited..

Ann: Response to ASX Query, page-21

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 214 Posts.
    lightbulb Created with Sketch. 44
    I am no expert, but I'd assume the pharma industry is as cut throat as any other industry where this money is involved.
    So, having listened to the presentation at the 39th JP Morgan whatever and reading the report, I would think that some big pharma was listening and that the very next thing said big pharma would do is to check if Paradigm has a chink in their armor.
    Check the phase 2 results to see if they think this might work or not.
    Check patents.
    Check supply agreements.
    Check with their buddies in the FDA if a few palms can be greased (joking, I am sure all of this is completely above board).
    Etc.
    Why pay premium for a company if you can run the trials in half the time for a fraction of the cost of a takeover should there indeed be a chink in Paradigm's armor.
    Hopefully they then find everything stitched up neatly, after which they will start to purchase shares to a point where they have to declare it (no idea how that works) after which they will want to talk shop.
    And I think this is all about to go down in the next two weeks or so.

    I really hope Yamaha brings out a fishing jetski this year: cause I am ordering one right now!
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
22.5¢
Change
0.010(4.65%)
Mkt cap ! $78.73M
Open High Low Value Volume
22.0¢ 23.5¢ 21.5¢ $288.5K 1.279M

Buyers (Bids)

No. Vol. Price($)
6 130626 22.5¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 60000 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.